

	Type	L #	Hits	Search Text	Dbs	Time Stamp	Comments	Error Definition	Error Rows
1	BRS	L1	99047	pharmaceutical adj composition	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/07 09:23			0
2	BRS	L2	33202	succinate	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/07 09:23			0
3	BRS	L3	91920	active adj agent	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/07 09:23			0
4	BRS	L4	5382	(insulin-like adj growth adj factor) or IGF-1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/07 09:24			0
5	BRS	L6	0	1 same 2 same 4	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/07 09:24			0
6	BRS	L5	8	1 same 2 same 3	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/07 09:26			0
7	BRS	L7	4	tonicifying adj agent	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/07 09:27			0
8	BRS	L8	11288	sodium adj chloride	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/07 09:27			0
9	BRS	L9	0	5 same (7 or 8)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/07 09:27			0

=> d his

(FILE 'HOME' ENTERED AT 09:32:11 ON 07 NOV 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA'
ENTERED AT

09:32:38 ON 07 NOV 2002

L1 22015 S PHARMACEUTICAL COMPOSITION
L2 113928 S SUCCINATE
L3 42256 S ACTIVE AGENT
L4 114163 S (INSULIN-LIKE GROWTH FACTOR) OR IGF-1
L5 1 S L1 (P) L2 (P) L3
L6 0 S L1 (P) L2 (P) L4
L7 13 S L2 (P) (L3 OR L4) (P) COMPOSITION
L8 13 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)
L9 2 S TONICIFYING AGENT
L10 0 S L8 (P) L9
L11 203042 S SODIUM CHLORIDE
L12 0 S L8 (P) L11

=> log y

FILE 'HOME' ENTERED AT 09:32:11 ON 07 NOV 2002

=> file medline caplus biosis embase scisearch agricola		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 09:32:38 ON 07 NOV 2002

FILE 'CAPLUS' ENTERED AT 09:32:38 ON 07 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:32:38 ON 07 NOV 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 09:32:38 ON 07 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 09:32:38 ON 07 NOV 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'AGRICOLA' ENTERED AT 09:32:38 ON 07 NOV 2002

=> s pharmaceutical composition
5 FILES SEARCHED...
L1 22015 PHARMACEUTICAL COMPOSITION

=> s succinate
L2 113928 SUCCINATE

=> s active agent
L3 42256 ACTIVE AGENT

=> s (insulin-like growth factor) or IGF-1
4 FILES SEARCHED...
L4 114163 (INSULIN-LIKE GROWTH FACTOR) OR IGF-1

=> s l1 (p) l2 (p0 L3
MISSING OPERATOR 'L14 (P0'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l1 (p) l2 (p) L3
L5 1 L1 (P) L2 (P) L3

=> d l5 1 ibib abs

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:416803 CAPLUS
DOCUMENT NUMBER: 135:24708
TITLE: A rapid acting freeze-dried oral pharmaceutical
composition for treating migraine
INVENTOR(S): Venkateswara Rao, Pavuluri; Khadgapathi, Podili
PATENT ASSIGNEE(S): Natco Pharma Limited, India
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001039836	A1	20010607	WO 2000-IN78	20000825
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,			

MD, MG, MK, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1246668 A1 20021009 EP 2000-983475 20000825

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.: IN 1999-MA1160 A 19991201
WO 2000-IN78 W 20000825

AB The present invention relates to a novel rapid-acting freeze-dried
pharmaceutical ***compn*** . useful for the treatment of
migraine and assocd. symptoms at a reduced total dose of active substance
than required for oral administration in the form of a tablet. The compn.
contains a porous matrix network of a water sol. or water dispersible
carrier material, a pharmaceutically active substance(s), organoleptic
additives such as sweetening agents, flavoring agents, and coloring
agents, pharmaceutically acceptable preservatives, solubilizing agents,
surface ***active*** ***agents*** and/or buffering agents. The
pharmaceutical ***compn*** . optionally may contain other
additives such as permeation enhancers, chelating salts and stabilizing
agents. Advantages of the invention are: (1) rapid onset of action due to
the rapid absorption of the active substance through oral mucosa, (2)
reduced dosage of the drugs as absorption through oral mucosa bypasses the
first-pass metab. and overcomes possible degrdn. in the gastrointestinal
tract, (3) easy to administer to pediatric and geriatric patients, and (4)
medicament can be taken without water. For example, tablets were prepd.
by freeze drying to contain sumatriptan ***succinate*** 14.00 mg,
ondansetron hydrochloride 5.0 mg, citric acid 1.68 mg, Na2HPO4 2.42 mg,
polyvinyl chloride 3.0%, mannitol 25%, Me paraben sodium 0.1%, and Pr
paraben sodium 0.01%.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 09:32:11 ON 07 NOV 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
09:32:38 ON 07 NOV 2002

L1 22015 S PHARMACEUTICAL COMPOSITION
L2 113928 S SUCCINATE
L3 42256 S ACTIVE AGENT
L4 114163 S (INSULIN-LIKE GROWTH FACTOR) OR IGF-1
L5 1 S L1 (P) L2 (P) L3

=> s l1 (p) l2 (p) l4
L6 0 L1 (P) L2 (P) L4

=> s l2 (p) (l3 or l4) (p) composition
L7 13 L2 (P) (L3 OR L4) (P) COMPOSITION

=> duplicate remove l7
PROCESSING COMPLETED FOR L7
L8 13 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)

=> d l8 1-13 ibib abs

L8 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:332011 CAPLUS
DOCUMENT NUMBER: 136:355482
TITLE: Compositions comprising a polypeptide and an active
agent
INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randall
J.
PATENT ASSIGNEE(S): New River Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034237	A1	20020502	WO 2001-US26142	20010822
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001086599	A5	20020506	AU 2001-86599	20010822

PRIORITY APPLN. INFO.:

US 2000-642820 A 20000822
WO 2001-US26142 W 20010822

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the compn. to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepd. from Glu(OBut)NCA and cephalixin hydrochloride.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:556104 CAPLUS

DOCUMENT NUMBER: 137:109489

TITLE: Compositions comprising a polypeptide and an active agent

INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randal J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 34 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002099013	A1	20020725	US 2001-933708	20010822
PRIORITY APPLN. INFO.:			US 2000-247556P P	20001114
			US 2000-247558P P	20001114
			US 2000-247559P P	20001114
			US 2000-247560P P	20001114
			US 2000-247561P P	20001114
			US 2000-247594P P	20001114
			US 2000-247595P P	20001114
			US 2000-247606P P	20001114
			US 2000-247607P P	20001114
			US 2000-247608P P	20001114
			US 2000-247609P P	20001114
			US 2000-247610P P	20001114
			US 2000-247611P P	20001114
			US 2000-247612P P	20001114
			US 2000-247620P P	20001114
			US 2000-247621P P	20001114
			US 2000-247634P P	20001114
			US 2000-247635P P	20001114
			US 2000-247698P P	20001114
			US 2000-247699P P	20001114
			US 2000-247700P P	20001114
			US 2000-247701P P	20001114
			US 2000-247702P P	20001114
			US 2000-247797P P	20001114
			US 2000-247798P P	20001114
			US 2000-247799P P	20001114

US 2000-247800P P 20001114
 US 2000-247801P P 20001114
 US 2000-247802P P 20001114
 US 2000-247803P P 20001114
 US 2000-247804P P 20001114
 US 2000-247805P P 20001114
 US 2000-247807P P 20001114
 US 2000-247832P P 20001114
 US 2000-247833P P 20001114
 US 2000-247926P P 20001114
 US 2000-247927P P 20001114
 US 2000-247928P P 20001114
 US 2000-247929P P 20001114
 US 2000-247930P P 20001114

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the compn. to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepd. from Glu(OBut)NCA and cephalixin hydrochloride.

L8 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:416803 CAPLUS
 DOCUMENT NUMBER: 135:24708
 TITLE: A rapid acting freeze-dried oral pharmaceutical composition for treating migraine
 INVENTOR(S): Venkateswara Rao, Pavuluri; Khadgapathi, Podili
 PATENT ASSIGNEE(S): Natco Pharma Limited, India
 SOURCE: PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001039836	A1	20010607	WO 2000-IN78	20000825
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1246668	A1	20021009	EP 2000-983475	20000825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLN. INFO.:		IN 1999-MA1160 A 19991201 WO 2000-IN78 W 20000825		

AB The present invention relates to a novel rapid-acting freeze-dried pharmaceutical ***compn*** . useful for the treatment of migraine and assocd. symptoms at a reduced total dose of active substance than required for oral administration in the form of a tablet. The ***compn*** . contains a porous matrix network of a water sol. or water dispersible carrier material, a pharmaceutically active substance(s), organoleptic additives such as sweetening agents, flavoring agents, and coloring agents, pharmaceutically acceptable preservatives, solubilizing agents, surface ***active*** ***agents*** and/or buffering agents. The pharmaceutical ***compn*** . optionally may contain other additives such as permeation enhancers, chelating salts and stabilizing agents. Advantages of the invention are: (1) rapid onset of action due to the rapid absorption of the active substance through oral mucosa, (2) reduced dosage of the drugs as absorption through oral mucosa bypasses the first-pass metab. and overcomes possible degrdn. in the gastrointestinal tract, (3) easy to administer to pediatric and geriatric patients, and (4) medicament can be taken without water. For example, tablets were prepd. by freeze drying to contain sumatriptan ***succinate*** 14.00 mg, ondansetron hydrochloride 5.0 mg, citric acid 1.68 mg, Na2HPO4 2.42 mg,

polyvinyl chloride 3.0%, mannitol 25%, Me paraben sodium 0.1% and Pr
paraben sodium 0.01%.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:277849 CAPLUS

DOCUMENT NUMBER: 132:313700

TITLE: Pharmaceutical formulations useful to treat
inflammatory and immune disorders

INVENTOR(S): Yeh, C. Grace; Dow, Gordon J.; Lathrop, Robert W.;
Chorghade, Mukund S.; Rao, Alla Verkata Rama

PATENT ASSIGNEE(S): Leukosite, Inc., USA

SOURCE: PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023071	A1	20000427	WO 1999-US24361	19991015
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1123095	A1	20010816	EP 1999-955021	19991015
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRIORITY APPLN. INFO.:			US 1998-173903 A 19981016	
			WO 1999-US24361 W 19991015	

OTHER SOURCE(S): MARPAT 132:313700

GI

/ Structure 1 in file .gra /

AB A pharmaceutical formulation is provided for the treatment of inflammatory and/or immune disorders, particularly those mediated by platelet activating factor ("PAF") or a product of 5-lipoxygenase. An example compd., CMI-392 (I) was prepd. and ***compns*** may contain this compd. or similar compds. and an enhancer ***compn*** contg. one or more C3-18 esters such as di-Et ***succinate***, propylene carbonate, diisopropyl adipate and glyceryl triacetate. In another embodiment, the formulation is a cream, gel, lotion, oil, or the like, contg. the ***active*** ***agent*** in cryst. form. The invention also encompasses the novel cryst. form of the ***active*** ***agent***, and methods for using the formulations to treat individuals with inflammatory and/or immune disorders. Also encompassed is use of iso-Pr alc. (IPA) to enhance stability of the ***active*** ***agent*** and pharmaceutical formulations.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:14987 CAPLUS

DOCUMENT NUMBER: 132:83652

TITLE: Aqueous compositions containing corticosteroids for
nasal and pulmonary delivery

INVENTOR(S): Saidi, Zahir; Klyashchitsky, Boris

PATENT ASSIGNEE(S): LDS Technologies, Inc., USA

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000000181	A1	20000106	WO 1999-US14351	19990624
W: AU, CA, IL, JP, MX, NO, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6241969	B1	20010605	US 1998-105838	19980626
AU 9947171	A1	20000117	AU 1999-47171	19990624
EP 1089715	A1	20010411	EP 1999-930689	19990624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002519318	T2	20020702	JP 2000-556766	19990624
PRIORITY APPLN. INFO.: US 1998-105838 A2 19980626 WO 1999-US14351 W 19990624				

AB The present invention provides ***compsns*** . contg. corticosteroid compds. as ***active*** ***agents*** for the treatment of ailments and diseases of the respiratory tract, particularly the lungs, by way of nasal and pulmonary administration. The corticosteroid compds. are present in a dissolved state in the ***compsns*** . The ***compsns*** . can be formulated in a concd., essentially non-aq. form for storage or in a dild., aq.-based form for ready delivery. The corticosteroid ***compn*** . contains an ethoxylated deriv. of vitamin E and/or a polyethylene glycol fatty acid ester as the high-HLB surfactant present in the formulation. The ***compsns*** . are ideally suited for inhaled delivery with a nebulizer or for nasal delivery. Thus, beclomethasone dipropionate monohydrate (2.8 mg) was dissolved in 997.2 mg of a 2:1 wt./wt. mixt. of PEG-200 and .alpha.-tocopherol polyethylene glycol ***succinate*** and the dild. (1:6.65 by vol.) with water. The final soln. contained 420 .mu.g beclomethasone dipropionate/mL of soln.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:659215 CAPLUS
DOCUMENT NUMBER: 131:276983
TITLE: Matrixes for controlled drug release
INVENTOR(S): Bar-Shalom, Daniel
PATENT ASSIGNEE(S): BM Research A/S, Den.
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951208	A1	19991014	WO 1999-DK174	19990325
W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2327685	AA	19991014	CA 1999-2327685	19990325
AU 9930243	A1	19991025	AU 1999-30243	19990325
EP 1067910	A1	20010117	EP 1999-911627	19990325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002510616	T2	20020409	JP 2000-541979	19990325
PRIORITY APPLN. INFO.: EP 1998-610009 A 19980403 WO 1999-DK174 W 19990325				

AB The present invention relates to a ***compn*** . for controlled delivery of at least one active substance into an aq. medium by erosion at

a preprogrammed rate of at least one surface of the ***compn***. The ***compn*** comprises a matrix which is erodible in the medium and which allows substantially no diffusion of water into the ***compn***. beyond any exposed surface layers of the matrix, the matrix comprising at least one substantially water-sol. cryst. polymer, e.g. a polyethylene glycol, with at least one water-dispersible or water-sol. surface ***active***, e.g. a nonionic emulsifier, dispersed therein, at least one release modifier, e.g. an enteric coating material, that functions to regulate erosion of the matrix within a pH of 2-7, and at least one active substance. The ***compn*** provides controlled, e.g. substantially zero order, release in both the stomach and the intestines despite different conditions of pH, agitation and absorption. An oral ***compn*** was formulated contg. PEG-35,000 32, nifedipine 55, hydroxypropyl Me cellulose acetate ***succinate*** (AQUOAT) 2.5, tartrazine 1, Et cellulose 2.5, and PEG 2000 monostearate 7 %. A dissoln. test result (USP XXIII method), showed the ***compn*** gave substantially zero order release over a period of about 10 h.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:816016 CAPLUS

DOCUMENT NUMBER: 130:57218

TITLE: Unit dosage forms for treatment of vasoconstriction and related conditions

INVENTOR(S): Richardson, Kenneth T.; Pearson, Don C.

PATENT ASSIGNEE(S): Chronorx LLC, USA

SOURCE: U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 753,967, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5849338	A	19981215	US 1997-849068	19970826
WO 9737670	A1	19971016	WO 1997-US4286	19970318
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1996-753967 B2 19961204
WO 1997-US4286 W 19970318
US 1996-15115P P 19960410

AB Magnesium is formulated in combination with vitamin E, vitamin C, folate, selenium, and optionally melatonin in a unit dosage form for oral administration, for the treatment of vasoconstriction and the physiol. and pathol. conditions giving rise to vasoconstriction. These ***active*** ***agents*** complement each other in suppressing these conditions, using a variety of mechanisms operating in conjunction with one another. The inclusion of magnesium in a plurality of forms provides addnl. advantages in terms of controlling and sustaining the release of magnesium in locations along the digestive tract where the magnesium will have its greatest effectiveness as a therapeutic agent, thus improving control over the clin. bioavailability of magnesium and in improving the selection of appropriate therapeutic ranges. Thus, single layer tablet, substantially homogeneous in ***compn***, which will disintegrate upon ingestion to provide simultaneous accessibility to all components, was prepd. from magnesium acetate tetrahydrate 67.67, magnesium ascorbate 64.17, magnesium citrate pentahydrate 54.36, MgO 118.54, magnesium stearate 3.55, selenophenol or selenomethanol 0.10, melatonin 0.1-40, and folic acid 0.20, and starch 120.00 mg/tablet and vitamin E acid ***succinate*** 60 IU.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1997:390077 CAPLUS
 DOCUMENT NUMBER: 127:39874
 TITLE: Manufacture of controlled-release enteric-coated oral preparations
 INVENTOR(S): Okamoto, Koichi; Kobayashi, Masaru
 PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09100226	A2	19970415	JP 1995-282659	19951003

AB Controlled-release enteric-coated ***compns*** . which have improved appearance, strength, and stability, are manufd. by spraying molten waxes and enteric-sol. fine powders onto a solid form contg. pharmacol. ***active*** ***agents*** . Phenylpropanolamine.cntdot.HCl was sprayed onto Nonpareil-101 using a PVP soln. The above solid particles were introduced in a fluidized bed and coated with melted glycerol distearate and hydroxypropyl Me cellulose acetate ***succinate*** powder (av. diam. <10 .mu.m).

L8 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1974:56462 CAPLUS
 DOCUMENT NUMBER: 80:56462
 TITLE: Agricultural and horticultural fungicides
 INVENTOR(S): Fujikawa, Kanichi; Haga, Takahiro; Shigehara, Itaru; Komiyoji, Terumasa
 PATENT ASSIGNEE(S): Ishihara Mining and Chemical Co., Ltd.
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48072322	A2	19730929	JP 1972-3101	19711229

AB Agricultural or horticultural fungicides contg. N-(3-chlorophenyl)-N'-(4-chlorophenyl)acetamidine (I) [50978-68-2], N-phenyl-N'-(4-chlorophenyl)acetamidine [50978-69-3] and(or) their chloride, sulfate, or ***succinate*** salts as ***active*** ***agents*** were prepd. These fungicides were particularly effective for rice blight and cucumber anthracnose, and also effective against mildew disease. These fungicides may be used in combination with other fungicides, insecticides and plant growth regulators. A typical ***compn*** . is prepd. by mixing I (20 parts), diclight powder (sic) (75 parts) and Na-ligninsulfonate [8061-51-6] (5 parts). Application of I at 500 ppm (20 ml/pot) to rice plants prior to inoculation of Pellicularia [Corticium] sasakii was 100% effective in controlling the infestation.

L8 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1970:33548 CAPLUS
 DOCUMENT NUMBER: 72:33548
 TITLE: Polyfunctional surface-active agents
 PATENT ASSIGNEE(S): SINNOVA
 SOURCE: Fr., 3 pp.
 CODEN: FRXXAK
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 1561451		19690328	FR	19680214

AB Surface- ***active*** ***agents*** of the general ***compn*** .

N-(monoalkyl ***succinate***) ethylenediamine or N-(monoalkyl ***succinate***) -1,3-propanediamine, in which the alkyl group is a linear C7-27 group, have an amphoteric and chelating character. Good detergency in the range of pH 5.8-10 is obtained.

L8 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1967:509956 CAPLUS
DOCUMENT NUMBER: 67:109956
TITLE: Detergent composition containing mixed anionic-cationic surfactants
INVENTOR(S): Speel, Henry C.
PATENT ASSIGNEE(S): Universal Oil Products Co.
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3345300		19671003	US	19521210

AB A laundering ***compn*** . contg. a mixt. of a cationic surface-
active ***agent*** contg. a quaternary ammonium radical and a
hydrophobic hydrocarbon group and an anionic detergent consisting of a
monoalkali metal salt of a polybasic carboxylic acid monoester of the
terminal alkylol group of a polyoxyalkylenated org. compd. contg. a
hydrophobic hydrocarbon radical at the opposite end of the
poly(oxyalkylene) chain were described. Thus, nonylphenol prepd. by
alkylation of PhOH with a trimer of propylene in the presence of BF3 was
oxyethylenated with ethylene oxide by heating a mixt. of 8 moles ethylene
oxide, 1 mole nonylphenol, and 0.6 wt. % NaOEt at 135.degree.F. and 5 atm.
N until a drop in pressure indicated completion of the reaction. The
product was heated for 3 hrs. with a molar excess of succinoyl chloride at
110.degree., neutralized with NaOH, and hydrolyzed by adding 30% excess
NaOH and heating for 1.5 hrs. at 110.degree.. A 0.3% aq. soln. of the
product has a detergency of 120% at 140.degree.F., compared with 100% for
a standard Na dodecylbenzenesulfonate soln. A mixt. of 50 parts of this
Na ***succinate*** ester of polyoxyethylenated nonylphenol and 50
parts Ammonyx G (95% active paste) gave a laundering ***compn*** . that
was completely sol. in H2O at 140.degree.F. at concns. .gtoreq.5 wt. %.
This ***compn*** . had good fabric texture-inducing properties.
Similar results were obtained by using dodecylphenol, dodecanol,
dodecylaniline, or stearic acid as the starting material and o-phthalic
acid or malonic acid.

L8 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1967:19421 CAPLUS
DOCUMENT NUMBER: 66:19421
TITLE: Remoistenable gummed sheets
INVENTOR(S): Nelson, George R.; Botsaris, Gregory D.
PATENT ASSIGNEE(S): Dennison Manufg. Co.
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3285764		19661115	US	19620525

AB Coating ***compsns*** . for water-remoistenable gummed sheets are prepd.
from a dispersion of an aq. soln. of a water-activable gum in which the
liquid carrier is sufficiently immiscible with water to keep the water
soln. dispersed. The dispersion contains a nonvolatile surface-
active ***agent*** soluble in the carrier and having both a
hydrophilic and hydrophobic portion. Thus, a 50% aq. soln. of a 1:1 mixt.
of corn dextrin and bone glue (I) which had a viscosity of 275 mp. at 25%
concn. was prepd. by cooking the dextrin and lowering the temp. to
120.degree. while adding the glue. The pH was adjusted to 5.8 with HCl.
Also, 100 parts PhMe and 2.4 parts dioctyl Na sulfo- ***succinate***

were mixed and 100 parts I was added at 120.degree.F. The emulsion was applied at 4 lb./ream, dried, and steamed flat. The gum film had good cohesion and adhesion to the paper backing and had better quick-tack and adhesiveness than controls. Hide glue was also used as a water-reactivable gum and other surface- ***active*** ***agents*** used were di-tridecyl Na sulfosuccinate, dihexyl Na ***succinate*** (Nekal NS), alkyl aryl polyether alc. (Triton X100), ethyl cellulose, dioctyl Na sulfosuccinate, and didecyl Na sulfoadipate.

L8 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1967:48103 CAPLUS
DOCUMENT NUMBER: 66:48103
TITLE: Lubricant additives
PATENT ASSIGNEE(S): Mobil Oil Corp.
SOURCE: Neth. Appl., 20 pp.
CODEN: NAXXAN
DOCUMENT TYPE: Patent
LANGUAGE: Dutch
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 6603247		19661006		

PRIORITY APPLN. INFO.: US 19650405

AB The prepn. of phosphorodithioatoalkyl carboxylates by treating an O,O'-hydrocarbyl phosphorodithioate with an alkenyl carboxylate or by treating an alkali metal salt of the dithioic acid with an .alpha.-haloalkyl carboxylate or an .alpha.-toxylalkylcarboxylate and the use of these compds. as antioxidant in lubricant ***compns*** are described. Thus, 222 g. P2S5 was added with stirring to 296 g. BuOH at 75.degree. over 1 hr., the temp. was raised to 90.degree. and kept at 90.degree. to give O,O'-di-iso-Bu phosphorodithioate (I). Vinyl acetate (258.3 g.) was added dropwise to 484.6 g. I over 0.5 hr. while the temp. was kept at 78.degree., the mixt. was heated 1 hr. at 85-90.degree., and unchanged vinyl acetate removed to give 650.9 g. (99%) 1-(O,O'-diisobutyl phosphorodithioato)ethyl acetate (II). II was also obtained as follows. A soln. of 210.7 g. K O,O'-di iso-Bu phosphorodithioate in 150 cc. HCONMe2 was added dropwise with stirring to 121.4 g. 1-chloroethyl acetate in 100 cc. HCONMe2 over 20 min. at 30-5.degree., the temp. was raised to 62.degree., stirring and heating continued 1 hr., the product washed with H2O, extd. with C6H6, washed again with H2O, the C6H6 removed, and the residue distd. at 0.01 mm. to give 165 g. II. Similarly was prepd. 453 g. 1-(O,O'-dioleyl phosphorodithioato)ethyl acetate (III) from O,O'-diallyl phosphorodithioate (prepd. by the conversion of 400 g. oleyl alc. and 100 g. P2S5) at 45.degree., addn. of 103 g. vinyl acetate, heating at 85-90.degree., and distn. at 100.degree./0.2 mm. Other compds. prepd. were (compd. and percentage yield given): 1-(O,O'-bis-(2,2,4-trimethylpentyl) phosphorodithioato)ethyl acetate (IV), 96%; 1-(O,O'-diphenyl phosphorodithioato)ethyl acetate (V), -; 1-[O,O'-bis(nonylphenyl) phosphorodithioato]ethyl acetate (VI), 96%; 1-(O,O'-dimethylphosphorodithioato)ethylacetate, (VII), 82%; 1-(O,O'-diisopentyl phosphorodithioato)ethyl acetate, (VIII), 95%; 1-(O,O'-diisobutyl phosphorodithioato)ethyl benzoate (IX), 100%; 1-[O,O'-bis(1,3-dimethylbutyl)phosphorodithioato]ethyl acetate (XVI), -; 1-(O,O'-diisobutyl phosphorodithioato)ethyl butyrate (X) -; 1-[O,O'-di(butylphenyl) phosphorodithioato]ethyl propionate (XI), -; 1(O-alkyl-O'-alkyl phosphorodithioato)-ethyl acetate (XII). To bis(1-chloroethyl) ***succinate***, prepd. by treatment of 26.7 g. succinoyl chloride with 20 g. AcH in 100 cc. C6H6 contg. 0.2 g. ZnCl2, was added dropwise over 15 min. 97 g. K O,O'-di-iso-Bu phosphorodithioate in 150 cc. HCONMe2, and the mixt. heated to 80.degree. to give bis[1-(O,O'-diisobutyl phosphorodithioato)ethyl] ***succinate*** (XIII). Also prepd. was 1-(O,O'-diisodecyl phosphorodithioato)ethyl acetate (XIV) (100% yield) and 1-[O,O'-bis(2,2,4-trimethyl-3-hydroxypentyl) phosphorodithioato]ethyl acetate (XV). The products were tested for oxidn. stability when present in mineral oil ***compns***, and the ***compns*** were tested for corrosivity of Cu-Pb bearings. The results were (wt.-% P in oxidn.-stability expt., and loss in wt. of bearing in mg. given): II, 0.087, 4; III, 0.098, 8; IV, <0.036, 50; V, 0.035, -; VI, 0.021, 43 (surface- ***active*** ***agent*** present); VII, 0.112, 22; VIII, 0.039, 39 (surface- ***active***

agent present); IX, 0.024, 43; X, 0.086, 46; XI, 0.030, 50; XII, 0.036, -; XIII, 0.09, -; XIV, 0.059, 25 (surface- ***active***
 agent present); XV, 0.044, 33 (surface- ***active***
 agent present). No addn. of the products prepd. gave a loss of 3669 mg. Also tested were the results at a very high pressure whereby corrosion occurred with the use of IV at 122.595 kg. and with XVI at 122.601 kg. Thermal stability was also tested. For compds. of the general formula (RO)2P(S)SCHR2O2CnR1. The results were as tabulated.
 [TABLE OMITTED]

=> d his

(FILE 'HOME' ENTERED AT 09:32:11 ON 07 NOV 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 09:32:38 ON 07 NOV 2002

```
L1      22015 S PHARMACEUTICAL COMPOSITION
L2      113928 S SUCCINATE
L3      42256 S ACTIVE AGENT
L4      114163 S (INSULIN-LIKE GROWTH FACTOR) OR IGF-1
L5          1 S L1 (P) L2 (P) L3
L6          0 S L1 (P) L2 (P) L4
L7      13 S L2 (P) (L3 OR L4) (P) COMPOSITION
L8      13 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)
```

=> s tonicifying agent

```
L9      2 TONICIFYING AGENT
```

=> s l8 (p) l9

```
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L58 (P) L51'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L62 (P) L53'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L64 (P) L54'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L66 (P) L55'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L68 (P) L56'
L10      0 L8 (P) L9
```

=> s sodium chloride

```
L11     203042 SODIUM CHLORIDE
```

=> s l8 (p) l11

```
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L78 (P) L71'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L82 (P) L73'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L84 (P) L74'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L86 (P) L75'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L88 (P) L76'
L12      0 L8 (P) L11
```

=> d his

(FILE 'HOME' ENTERED AT 09:32:11 ON 07 NOV 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 09:32:38 ON 07 NOV 2002

```
L1      22015 S PHARMACEUTICAL COMPOSITION
L2      113928 S SUCCINATE
L3      42256 S ACTIVE AGENT
L4      114163 S (INSULIN-LIKE GROWTH FACTOR) OR IGF-1
L5          1 S L1 (P) L2 (P) L3
L6          0 S L1 (P) L2 (P) L4
L7      13 S L2 (P) (L3 OR L4) (P) COMPOSITION
L8      13 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)
```

L9 2 S TONICIFYING AGE
L10 0 S L8 (P) L9
L11 203042 S SODIUM CHLORIDE
L12 0 S L8 (P) L11

=> log y

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

67.14

67.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY

TOTAL
SESSION

CA SUBSCRIBER PRICE

-8.67

-8.67

STN INTERNATIONAL LOGOFF AT 09:39:28 ON 07 NOV 2002